Publications
Detailed Information
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Lee, J. -K. | - |
dc.contributor.author | Ahn, M. -J. | - |
dc.contributor.author | Kim, D. -W. | - |
dc.contributor.author | Sun, J. -M. | - |
dc.contributor.author | Keam, B. | - |
dc.contributor.author | Kim, T. M. | - |
dc.contributor.author | Heo, D. S. | - |
dc.contributor.author | Ahn, J. S. | - |
dc.contributor.author | Choi, Y. -L. | - |
dc.contributor.author | Min, H. -S. | - |
dc.contributor.author | Jeon, Y. K. | - |
dc.contributor.author | Park, K. | - |
dc.date.accessioned | 2020-04-27T11:05:57Z | - |
dc.date.available | 2020-04-27T11:05:57Z | - |
dc.date.created | 2018-07-26 | - |
dc.date.issued | 2017-02 | - |
dc.identifier.citation | Annals of Oncology, Vol.28 No.2, pp.292-297 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 41332 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165246 | - |
dc.description.abstract | Background: Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed this study to examine the efficacy and safety of vandetanib 300 mg daily in this patient population. Patients and methods: This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0-2. The primary endpoint was the objective response rate. Results: A total of 18 patients were enrolled in this study between July 2013 and October 2015. Patients were aged 35-71 years; three had a performance status of 2, and the majority were a heavily pretreated population (two different previous chemotherapy regimens in 72% of the patients). Among the 17 evaluable patients, three had a partial response (objective response rate >= 18%) and eight had a stable disease (disease control rate = 65%). Among these patients, the partial response or disease stabilization was durable for more than 6 months in eight patients. Vandetanib also showed a progression-free survival of 4.5 months, and an overall survival of 11.6 months during a median follow-up duration of 14 months. The safety profile was comparable with previous studies of vandetanib. Most vandetanib-related adverse events were mild with prevalent hypertension and rash (in>70% of patients). Grade 3 toxicity included hypertension (n = 3), QT prolongation (2), and elevation of aminotransferases (1), and as a consequence the dose was reduced in four patients. There were no adverse events associated with grade 4 or 5 toxicity. Conclusion: Vandetanib is moderately active in pretreated patients with advanced NSCLC-harboring RET rearrangements. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 전윤경 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1093/annonc/mdw559 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000397278300015 | - |
dc.identifier.scopusid | 2-s2.0-85019621936 | - |
dc.citation.endpage | 297 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 292 | - |
dc.citation.volume | 28 | - |
dc.identifier.sci | 000397278300015 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, D. -W. | - |
dc.contributor.affiliatedAuthor | Jeon, Y. K. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | THYROID-CANCER | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | FUSION | - |
dc.subject.keywordPlus | ALK | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordPlus | CRIZOTINIB | - |
dc.subject.keywordPlus | MEDULLARY | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordAuthor | vandetanib | - |
dc.subject.keywordAuthor | RET rearrangement | - |
dc.subject.keywordAuthor | non-small cell lung cancer | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.